| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Tovecimig | ES-104; NOV-1501; CTX-009; HD-B001A; HDB001A; TR-009; ABL001; ABL-001 | Phase 3 Clinical | Abl Bio Inc | Ampullary Carcinoma; Bile Duct Neoplasms; Biliary Tract Neoplasms; Cholangiocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Gallbladder Neoplasms; Glioblastoma; Rectal Neoplasms; Solid tumours | Details |
| Navicixizumab | OMP-305B83 | Phase 3 Clinical | Oncomed Pharmaceuticals Inc | Colorectal Neoplasms; Fallopian Tube Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details |
| Dilpacimab | ABT-165; DVD-Ig ABT-165 | Phase 1 Clinical | Abbvie Inc | Neoplasms; Solid tumours | Details |

